ClinicalTrials.gg
Active, not recruitingNCT06921421Updated Oct 9, 2026

Assessment Of Burn Severity and Extent Spatial Frequency Domain Imaging

An observational study in Burn and Burn Injury, sponsored by The Metis Foundation. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by The Metis Foundation · Observational

How we know

Updated Oct 9, 2026Now Active, not recruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.

Planned enrollment
46th of 61
15 · median 59
Started
2025
with 12 others
Observational
61 of 336
9 open now
Primary completion
2026-04
later than 11 of 50 live
Registered
318th of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 46th largest by planned enrollment of the 61 observational ones that give a count, is one of 13 that started in 2025, is one of 61 observational ones, reaches primary completion later than 11 of the 50 other live ones, and was the 318th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

The goal of this pilot clinical study is to evaluate the feasibility of collecting Spatial Frequency Domain Imaging (SFDI) data in patients with circulatory compromise due to thermal burns using the FDA-cleared Clarifi Imaging System and the next generation handheld m-Clarifi. Accurate assessment of burn depth and assessment at the point of care is an essential input for clinicians to plan proper treatment and management. SFDI has been shown to be a promising method to evaluate burn depth and extent within 24 hours in pre-clinical studies. The two feasibility goals of this study are as follows: 1) Do the values obtained with a commercial SFDI system provide utility in assessing burn depth in a clinical setting? And 2) Do Clarifi and m-Clarifi provide equivalent data when assessing subjects with burn injuries (biomarker imaging values, clinical workflow).

03

Conditions studied

  • Burn
  • Burn Injury

Browse trials for

Keywords

  • SFDI
  • Spatial Frequency Domain Imaging
  • Burn depth
  • Burn injury assessment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients receiving care at the US Army Institute of Surgical Research (USAISR) Burn Center with thermal burn injuries will be considered for enrollment into this study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18 years of age or older
  2. Thermal burns of any depth (superficial, deep partial thickness, or full thickness).

Exclusion criteria

Exclusion Criteria:

  1. Patients less than 18 years of age
  2. Pregnant or breastfeeding women
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testSpatial Frequency Domain Imaging

    Spatial Frequency Domain Imaging captures at specific timepoints.

06

What researchers measure

Primary outcomes

  1. Mean SFDI Scattering Parameter (mm-¹) at Burn Injury Sites Using Clarifi and m-Clarifi Imaging Systems

    This outcome will report the mean value of the scattering coefficient (μs'), a quantitative SFDI-derived biomarker that correlates with burn depth, measured at specified time points (Day 0, 3, 7, 14, and 21) using the Clarifi and m-Clarifi imaging systems. Higher scattering values are associated with deeper tissue damage.

    Time frame: From enrollment to 21 days

Secondary outcomes

  1. Correlation Between SFDI Scattering Parameter and Clinician-Determined Burn Depth

    This outcome evaluates the statistical correlation between SFDI scattering values and the burn depth classifications made by clinicians based on visual assessment and standard clinical criteria (e.g., superficial partial, deep partial, full thickness).

    Time frame: From enrollment to 21 days

Other outcomes

  1. Agreement Between Clarifi and m-Clarifi Devices in Measuring SFDI Scattering Parameter

    This outcome assesses the agreement between SFDI scattering measurements obtained from the Clarifi (FDA-cleared) and m-Clarifi (handheld prototype) devices at the same anatomical burn sites. Agreement will be quantified using Bland-Altman analysis and intraclass correlation coefficients (ICCs).

    Time frame: From enrollment to 21 days

07

Study locations

1 site
  • The United States Army Institute of Surgical Resarch
    Fort Sam Houston, Texas 78234, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Apr 2026, 10 months.

Of 58 non-industry observational studies under Burns, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's 10 months is below that.

Counting every sponsor, half of 70 studies reached it within 24 months; a quarter within 14 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Apr 2025 → Jun 2025, primary completion Dec 2025 → Apr 2026 and completion Dec 2025 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2025
First posted
Apr 10, 2025
StartActual
Jun 3, 2025was Apr 2025
Primary completionActual
Apr 10, 2026was Dec 2025
CompletionEst.
Oct 2026was Dec 2025
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 9, 2026
Start date
Apr 2025→Jun 3, 2025 (actual)
Oct 9, 2026
Primary completion
Dec 2025→Apr 10, 2026 (actual)
Oct 9, 2026
Study completion
Dec 2025→Oct 2026
Oct 9, 2026
Sponsor
Collaborators added: United States Army Institute of Surgical Research; collaborators removed: The United States Institute of Surgical Research
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Active, not recruiting
    Start date Apr 2025→Jun 3, 2025 (now actual)
    Primary completion Dec 2025→Apr 10, 2026 (now actual)
    Study completion Dec 2025→Oct 2026
    Sponsor Collaborators added: United States Army Institute of Surgical Research; collaborators removed: The United States Institute of Surgical Research
    + 5 other changes: index terms, verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06921421
Lead sponsor
The Metis Foundation
Collaborators
United States Army Institute of Surgical Research, Modulated Imaging Inc.
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Jun 3, 2025
Primary completion
Apr 10, 2026
Completion
Oct 2026 (estimated)
Last update
Oct 9, 2026

Study contacts

Rodney Chan, MD
principal investigator · The Metis Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion